Perrigo shares down 10% after company reports loss, sells Tysabri Drug Royalties

  Perrigo announced on Monday that it had signed a definitive agreement to divest its rights to the royalty stream from the global net sales of the multiple sclerosis drug Tysabri (natalizumab) to RPI Finance More...

Perrigo Boosted By FDA Warning On Sanofi SA Drug

– Perrigo is acquiring Ireland’s Elan, a beneficiary of royalties from rival multiple sclerosis treatment, Tysabri. – CEO Joseph C. Papa – A safety warning by the US Food and More...

Pharmaceutical industry giant Perrigo wins the $8.6 billion battle for Elan of Ireland

– There’s a lot happening in the pharmaceutical industry these days and one of the biggest deals so far this year will see US based Perrigo swallow up the Eire based Elan. Perrigo are the only non-Israeli More...